Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a biotechnology company dedicated to the development of novel therapies for severe, rare muscle disorders. Headquartered in Boulder, Colorado, the company is renowned for its innovative approach to treating diseases involving skeletal muscle. Founded with Series A financing from OrbiMed, Edgewise Therapeutics is focused on the discovery, development, and commercialization of orally bioavailable, small molecule therapies designed to address musculoskeletal diseases.
The core mission of Edgewise Therapeutics is to transform the lives of patients suffering from debilitating muscle conditions. The company’s clinical-stage biopharmaceutical expertise is reflected in its robust pipeline of potential treatments, which aim to offer improved patient outcomes and enhanced quality of life.
Among its current projects, Edgewise Therapeutics is working on several promising candidates that target specific muscle-related conditions. By leveraging advanced research methodologies and cutting-edge technology, the company is able to create therapies that are not only effective but also accessible to a broader patient population.
Financially, Edgewise Therapeutics is well-positioned with strong backing from investors and strategic partners. The company continues to achieve significant milestones in its development programs, further solidifying its reputation as a leader in the biopharmaceutical landscape.
In recent news, Edgewise Therapeutics has made noteworthy progress with its clinical trials and has expanded its research partnerships to expedite the development of its drug candidates. The latest developments underline the company's commitment to innovation and excellence in the field of muscle disease therapeutics.
- Location: Boulder, Colorado
- Core Focus: Novel therapies for rare muscle disorders
- Key Projects: Orally bioavailable small molecule therapies
- Partnerships: Supported by OrbiMed and other strategic investors
Edgewise Therapeutics (EWTX) announced significant progress, having completed enrollment in the ARCH study for EDG-5506 targeting Becker muscular dystrophy (BMD). A Natural History Trial for BMD has commenced, aiming to recruit around 150 participants. The company reported a net loss of $14.7 million or $0.30 per share for Q1 2022, with cash reserves of $265.8 million expected to sustain operations through 2024. Phase 2 trials for BMD and Duchenne muscular dystrophy (DMD) are planned for 2022, with interim data from the ARCH study anticipated in Q2 2022.
Edgewise Therapeutics (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference fireside chat is scheduled for May 10, 2022, at 8:40 am PT. The RBC Capital Markets Global Healthcare Conference fireside chat will occur on May 18, 2022, at 3:35 pm ET. Presentations will be webcast live and available for replay on Edgewise’s events page.
Edgewise Therapeutics (NASDAQ: EWTX) has launched a funded observational trial to study Becker Muscular Dystrophy (BMD) progression. Led by the GRASP consortium and Virginia Commonwealth University, the two-year study aims to recruit around 150 participants aged 8 and older across the U.S. and Europe. The trial will collect data to enhance understanding of BMD, which currently has no approved therapies in the U.S. Edgewise's lead candidate, EDG-5506, has received Fast Track designation and is anticipated to enter Phase 2 trials for BMD in 2022.
Edgewise Therapeutics (NASDAQ: EWTX) announced its participation in the Muscular Dystrophy Association Annual Conference from
Edgewise Therapeutics (EWTX) announced positive topline results from the EDG-5506 Phase 1b clinical trial for Becker muscular dystrophy (BMD). The trial demonstrated safety and significant reductions in muscle damage biomarkers, including 71% reduction in creatine kinase and 83% in troponin levels. The company plans to initiate Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) in 2022. As of December 31, 2021, Edgewise had $281 million in cash and equivalents. For 2021, R&D expenses totaled $32.2 million, contributing to a net loss of $42.8 million.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced its participation in the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 16, 2022. Senior management will engage in a fireside chat at 12 pm ET, which will be webcast live and available for replay. The company specializes in developing small molecule therapies for rare muscle disorders, utilizing a unique drug discovery platform aimed at treating severe neuromuscular and cardiac conditions. More details can be found on their website.
Edgewise Therapeutics (NASDAQ: EWTX) announced positive topline results from the Phase 1b clinical trial of EDG-5506, targeting Becker Muscular Dystrophy (BMD). The treatment was well-tolerated, with no serious adverse events reported. Notably, EDG-5506 significantly reduced muscle damage biomarkers, including creatine kinase (CK) by 71% and fast skeletal muscle troponin (TNNI2) by 83%. These findings suggest the drug's potential in preserving muscle function. Management will discuss these results in a webcast at 9:00 a.m. ET today.
Edgewise Therapeutics (NASDAQ: EWTX) plans to announce topline results from the Phase 1b clinical trial of EDG-5506 for Becker muscular dystrophy (BMD) on January 5, 2022. The event will feature expert commentary and details about the new open-label study ARCH. The trial has enrolled 7 participants and assessed a 20 mg dose for 14 days, focusing on safety and biomarkers for muscle damage. A follow-up Phase 2 clinical trial is anticipated to begin in the first half of 2022 for BMD and later in the year for Duchenne muscular dystrophy (DMD).
Edgewise Therapeutics (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, has announced its participation in the 4th Annual HEALTHCONx conference hosted by Evercore ISI on December 2. Senior management will engage in a fireside chat and one-on-one investor meetings. The webcast of the fireside chat will begin at 1 PM ET and will be available for replay. Edgewise Therapeutics focuses on developing small molecule therapies for rare muscle disorders, employing a holistic approach to drug discovery aimed at addressing significant unmet medical needs.
Edgewise Therapeutics (EWTX) announced positive topline results from its EDG-5506 Phase 1 MAD study, showing safety and tolerability in healthy volunteers and initiating dosing in Becker muscular dystrophy (BMD) patients. Phase 2 trials for BMD and Duchenne muscular dystrophy (DMD) are expected to start in 2022. Financially, the company reported $290 million in cash and marketable securities as of September 30, 2021, with a net loss of $12.9 million for Q3 2021. R&D expenses rose significantly, indicating ongoing investments in clinical trials and company growth.
FAQ
What is the current stock price of Edgewise Therapeutics (EWTX)?
What is the market cap of Edgewise Therapeutics (EWTX)?
What is Edgewise Therapeutics, Inc.?
Where is Edgewise Therapeutics located?
What is the core focus of Edgewise Therapeutics?
What are Edgewise Therapeutics' key projects?
Who financed Edgewise Therapeutics' Series A round?
Is Edgewise Therapeutics a public company?
What recent achievements has Edgewise Therapeutics made?
What kind of diseases is Edgewise Therapeutics targeting?
What type of therapies is Edgewise Therapeutics developing?
What makes Edgewise Therapeutics' treatments innovative?
